Phase II North Central Cancer Treatment Group study of 2- chlorodeoxyadenosine in patients with recurrent glioma

S Vincent Rajkumar, Patrick A. Burch, Suresh Nair, Robert P. Dinapoli, Bernd Scheithauer, Judith R. O'Fallon, Paul S. Etzell, John M. Leitch, Roscoe F. Morton, Randolph Stuart Marks

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

There is no standard treatment for patients with recurrent gliomas, and their prognosis remains poor. 2-Chlorodeoxyadenosine is a purine analogue that has significant activity in many low-grade lymphoproliferative disorders. The authors conducted a phase II study to determine the efficacy of 2-chlorodeoxyadenosine in patients with recurrent gliomas. Patients with a histologically confirmed primary brain tumor with evidence of progression after radiation therapy were eligible. Protocol treatment consisted of 2- chlorodeoxyadenosine 7.0 mg/m2 intravenously on days 1 through 5 every 28 days. For those with a history of prior nitrosourea therapy, the dose of 2- chlorodeoxyadenosine was reduced to 5.6 mg/m2 on days 1 through 5. Treatment was continued until progression or a maximum of 12 cycles. Fifteen patients with recurrent astrocytomas or oligoastrocytomas of all grades were entered in the study. Treatment was well tolerated. Major toxicities were myelosuppression and neurotoxicity. No responses were seen. The authors conclude that although 2-chlorodeoxyadenosine is well tolerated, no demonstrable activity in patients with recurrent gliomas was established.

Original languageEnglish (US)
Pages (from-to)168-171
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number2
DOIs
StatePublished - Apr 1999

Fingerprint

Cladribine
Glioma
Neoplasms
Therapeutics
Lymphoproliferative Disorders
Astrocytoma
Clinical Protocols
Brain Neoplasms
Radiotherapy

Keywords

  • 2-Chlorodeoxyadenosine
  • Brain tumors
  • Chemotherapy
  • Clinical trial
  • Recurrent gliomas

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II North Central Cancer Treatment Group study of 2- chlorodeoxyadenosine in patients with recurrent glioma. / Rajkumar, S Vincent; Burch, Patrick A.; Nair, Suresh; Dinapoli, Robert P.; Scheithauer, Bernd; O'Fallon, Judith R.; Etzell, Paul S.; Leitch, John M.; Morton, Roscoe F.; Marks, Randolph Stuart.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 22, No. 2, 04.1999, p. 168-171.

Research output: Contribution to journalArticle

Rajkumar, S Vincent ; Burch, Patrick A. ; Nair, Suresh ; Dinapoli, Robert P. ; Scheithauer, Bernd ; O'Fallon, Judith R. ; Etzell, Paul S. ; Leitch, John M. ; Morton, Roscoe F. ; Marks, Randolph Stuart. / Phase II North Central Cancer Treatment Group study of 2- chlorodeoxyadenosine in patients with recurrent glioma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1999 ; Vol. 22, No. 2. pp. 168-171.
@article{b347da3e311e496a8b85e1074bc0e779,
title = "Phase II North Central Cancer Treatment Group study of 2- chlorodeoxyadenosine in patients with recurrent glioma",
abstract = "There is no standard treatment for patients with recurrent gliomas, and their prognosis remains poor. 2-Chlorodeoxyadenosine is a purine analogue that has significant activity in many low-grade lymphoproliferative disorders. The authors conducted a phase II study to determine the efficacy of 2-chlorodeoxyadenosine in patients with recurrent gliomas. Patients with a histologically confirmed primary brain tumor with evidence of progression after radiation therapy were eligible. Protocol treatment consisted of 2- chlorodeoxyadenosine 7.0 mg/m2 intravenously on days 1 through 5 every 28 days. For those with a history of prior nitrosourea therapy, the dose of 2- chlorodeoxyadenosine was reduced to 5.6 mg/m2 on days 1 through 5. Treatment was continued until progression or a maximum of 12 cycles. Fifteen patients with recurrent astrocytomas or oligoastrocytomas of all grades were entered in the study. Treatment was well tolerated. Major toxicities were myelosuppression and neurotoxicity. No responses were seen. The authors conclude that although 2-chlorodeoxyadenosine is well tolerated, no demonstrable activity in patients with recurrent gliomas was established.",
keywords = "2-Chlorodeoxyadenosine, Brain tumors, Chemotherapy, Clinical trial, Recurrent gliomas",
author = "Rajkumar, {S Vincent} and Burch, {Patrick A.} and Suresh Nair and Dinapoli, {Robert P.} and Bernd Scheithauer and O'Fallon, {Judith R.} and Etzell, {Paul S.} and Leitch, {John M.} and Morton, {Roscoe F.} and Marks, {Randolph Stuart}",
year = "1999",
month = "4",
doi = "10.1097/00000421-199904000-00012",
language = "English (US)",
volume = "22",
pages = "168--171",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Phase II North Central Cancer Treatment Group study of 2- chlorodeoxyadenosine in patients with recurrent glioma

AU - Rajkumar, S Vincent

AU - Burch, Patrick A.

AU - Nair, Suresh

AU - Dinapoli, Robert P.

AU - Scheithauer, Bernd

AU - O'Fallon, Judith R.

AU - Etzell, Paul S.

AU - Leitch, John M.

AU - Morton, Roscoe F.

AU - Marks, Randolph Stuart

PY - 1999/4

Y1 - 1999/4

N2 - There is no standard treatment for patients with recurrent gliomas, and their prognosis remains poor. 2-Chlorodeoxyadenosine is a purine analogue that has significant activity in many low-grade lymphoproliferative disorders. The authors conducted a phase II study to determine the efficacy of 2-chlorodeoxyadenosine in patients with recurrent gliomas. Patients with a histologically confirmed primary brain tumor with evidence of progression after radiation therapy were eligible. Protocol treatment consisted of 2- chlorodeoxyadenosine 7.0 mg/m2 intravenously on days 1 through 5 every 28 days. For those with a history of prior nitrosourea therapy, the dose of 2- chlorodeoxyadenosine was reduced to 5.6 mg/m2 on days 1 through 5. Treatment was continued until progression or a maximum of 12 cycles. Fifteen patients with recurrent astrocytomas or oligoastrocytomas of all grades were entered in the study. Treatment was well tolerated. Major toxicities were myelosuppression and neurotoxicity. No responses were seen. The authors conclude that although 2-chlorodeoxyadenosine is well tolerated, no demonstrable activity in patients with recurrent gliomas was established.

AB - There is no standard treatment for patients with recurrent gliomas, and their prognosis remains poor. 2-Chlorodeoxyadenosine is a purine analogue that has significant activity in many low-grade lymphoproliferative disorders. The authors conducted a phase II study to determine the efficacy of 2-chlorodeoxyadenosine in patients with recurrent gliomas. Patients with a histologically confirmed primary brain tumor with evidence of progression after radiation therapy were eligible. Protocol treatment consisted of 2- chlorodeoxyadenosine 7.0 mg/m2 intravenously on days 1 through 5 every 28 days. For those with a history of prior nitrosourea therapy, the dose of 2- chlorodeoxyadenosine was reduced to 5.6 mg/m2 on days 1 through 5. Treatment was continued until progression or a maximum of 12 cycles. Fifteen patients with recurrent astrocytomas or oligoastrocytomas of all grades were entered in the study. Treatment was well tolerated. Major toxicities were myelosuppression and neurotoxicity. No responses were seen. The authors conclude that although 2-chlorodeoxyadenosine is well tolerated, no demonstrable activity in patients with recurrent gliomas was established.

KW - 2-Chlorodeoxyadenosine

KW - Brain tumors

KW - Chemotherapy

KW - Clinical trial

KW - Recurrent gliomas

UR - http://www.scopus.com/inward/record.url?scp=17144467877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144467877&partnerID=8YFLogxK

U2 - 10.1097/00000421-199904000-00012

DO - 10.1097/00000421-199904000-00012

M3 - Article

C2 - 10199452

AN - SCOPUS:17144467877

VL - 22

SP - 168

EP - 171

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 2

ER -